← Eichor
Condition: Ras Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Ras

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Comparative Study of Pharmacokinetics, Safety, and Immunogenicity of RPH-030 and Vectibix® in Patients With Metastatic
Phase 1 · 26 location(s) · R-Pharm · NCT07543744This Randomized Trial Aims to Investigate the Efficacy of Balanced Nutritional Tablets-Comprehensive Multivitamin and Mi
Phase 4 · 1 location(s) · General Committee of Teaching Hospitals and Institutes, Egyp · NCT06981936Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Phase 1/Phase 2 · 27 location(s) · Institut de Recherches Internationales Servier · NCT05786924FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-S
Phase 2 · 13 location(s) · Oncolytics Biotech · NCT07446322The Safety and Efficacy of Cetuximab Beta Plus Fruquintinib With or Without Immune Checkpoint Inhibitorrs in First-line
Phase 2 · 1 location(s) · Zhejiang University · NCT07257653Efficacy and Safety of Romiplostim N01 Combined With Rituximab in Patients With Oral TPO-RA-Refractory Primary Immune Th
NA · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT07206823A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
Phase 1 · 3 location(s) · RasCal Therapeutics, Inc. · NCT04678648Intermittent or Continuous Panitumumab Plus FOLFIRI for Left Sided RAS/B-RAF Wild-type Metastatic Colorectal Cancer
Phase 3 · 1 location(s) · National Cancer Institute, Naples · NCT06509126Salivary E-cadherin, Calprotectin, and Matrix Metalloproteinase-9 Levels in Recurrent Aphthous Stomatitis
Phase N/A · 1 location(s) · Selin Yeşiltepe · NCT07141758Effects of GLP-1 RAs on Human Lactation Outcomes
Phase N/A · 1 location(s) · University of Colorado, Denver · NCT07720414A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer
Phase 2 · 19 location(s) · Verastem, Inc. · NCT07644559XELOX +Bev +Tislelizumab for First-line Treatment of MSS/pMMR RAS-mutated mCRC
Phase 2 · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT05970302Evaluation of Plasma Renin Concentrations in Cardiac Surgery
Phase N/A · 1 location(s) · Mayo Clinic · NCT06895213FORTRAS: A Study of MSK-TCR5 in People With Solid Tumor Cancers
Phase 1 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT07638371A Study of HRS-2329 in Participants With Advanced Solid Tumors Harboring RAS Mutations or Amplifications
Phase 1 · 1 location(s) · Jiangsu HengRui Medicine Co., Ltd. · NCT07189949Cadonilimab in Combination With Bevacizumab and FOLFOX Regimen for the First-Line Treatment of Advanced Unresectable MSS
Phase 2 · 1 location(s) · Fudan University · NCT06218810Use of a Mobile Brain-Body Imaging Approach to Evaluate the Effects of Rhythmic Auditory Stimulation on Gait and Brain F
NA · 1 location(s) · Boston University Charles River Campus · NCT07659964ValproIc Acid to Potentiate Anti-EGFR Treatment Efficacy and Prevent/Revert Resistance in Colorectal Cancer
Phase 2 · 8 location(s) · National Cancer Institute, Naples · NCT06714357Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Muta
Phase 1/Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT03190941Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Me
Phase 3 · 1 location(s) · Genmab · NCT07702032Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Phase 1 · 1 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT03454035Short-Course Radiotherapy Followed by Neoadjuvant Chemotherapy, HLX07and Serplulimab in LARC
Phase 2 · 3 location(s) · Union Hospital, Tongji Medical College, Huazhong University · NCT06542588Dynamic Changes in Circulating Tumour Cells Protein Expression
Phase 2 · 1 location(s) · Matteo's Friends · NCT06314997Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
Phase 1/Phase 2 · 6 location(s) · Revolution Medicines, Inc. · NCT07397338cfDNA 5mC/5hmC Biomarkers to Predict Chemotherapy Response in Metastatic Colorectal Cancer
Phase N/A · 1 location(s) · City of Hope Medical Center · NCT07224815ICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRC
Phase 2 · 1 location(s) · Beijing Hospital · NCT06321081Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C M
Phase 1/Phase 2 · 53 location(s) · Revolution Medicines, Inc. · NCT06128551Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations
Phase 2 · 1 location(s) · N.N. Petrov National Medical Research Center of Oncology · NCT06229340Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Colorectal Cancer
Phase N/A · 1 location(s) · Blokhin's Russian Cancer Research Center · NCT06449989RAK-PRIDE: Optimizing Proton Pump Inhibitor Use Through Education and Intervention
NA · 1 location(s) · RAK Medical and Health Sciences University · NCT06858384
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.